Paclitaxel for injection will be approved for marketing

On August 17, Kelun pharmaceutical entered the administrative examination and approval stage for the listing application of four generic drugs for injection, which is expected to be officially approved in the near future. Albumin paclitaxel, developed by abraxis bioscience company of the United States, is a new preparation of paclitaxel combined with albumin. It overcomes the disadvantages of ordinary paclitaxel, such as poor water solubility, low efficiency and high side effects. In January 2005, it was approved by FDA for the treatment of breast cancer, and then approved for the treatment of lung cancer and pancreatic cancer. Privacy Policy